Yamaguchi Asami, Ogino Yoshio, Iwakoshi Chie, Karasawa Katsuhiro, Ohki Masahiko
Development Department, Vitacain Pharmaceutical Co, Ltd.
Gan To Kagaku Ryoho. 2011 Oct;38(10):1659-65.
Special use-results surveillance was conducted to examine the safety and efficacy of trigger point (TP) therapy by Neovitacain ®injection (NV) in the daily clinical treatment of myofascial pain in cancer patients. The case report forms of 175 patients were collected from 43 nationwide facilities and all of them were analyzed in terms of safety and efficacy. This treatment deeply impressed both patients and physicians; 75.4% and 78.3% respectively, over "the good". In addition, as the results of Wilcoxon's signed rank sum test for pain assessment (VAS, FS), both "Cumulative effect before and after treatment" and "Immediate effect before and after each administration" were confirmed to show a highly significant difference (p<0. 0001). Side effects were observed in five of 175 cases (2. 9%) but none of them were serious. Judging from the results of this study, TP therapy with NV was considered to be very useful for the treatment of myofascial pain in cancer patients.
开展了特殊用途-结果监测，以检验通过注射新维他卡因®（NV）进行触发点（TP）治疗在癌症患者肌筋膜疼痛日常临床治疗中的安全性和有效性。从全国43家机构收集了175例患者的病例报告表，并对所有病例报告表进行了安全性和有效性分析。这种治疗给患者和医生都留下了深刻印象；分别有75.4%和78.3%的人评价为“良好”以上。此外，作为疼痛评估（视觉模拟评分法、面部表情评分法）的Wilcoxon符号秩和检验结果，“治疗前后的累积效应”和“每次给药前后的即时效应”均被证实有极显著差异（p<0.0001）。175例中有5例（2.9%）观察到副作用，但均不严重。从本研究结果来看，NV触发点疗法被认为对癌症患者肌筋膜疼痛的治疗非常有用。
